BIO-RAD LABORATORIES, INC. (NYSE:BIO) Files An 8-K Shareholder Director NominationsITEM 5.08 Shareholder Director Nominations.
To the extent applicable, the information in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.
ITEM 8.01 Other Events
The Board of Directors (the “Board”) of Bio-Rad Laboratories, Inc. (the “Company”) has established Tuesday, April 23, 2019 as the date of the Company’s 2019 annual meeting of stockholders (the “2019 Annual Meeting”). Because the date of the 2019 Annual Meeting has advanced by more than 30 days from the anniversary date of the Company’s 2018 annual meeting of stockholders (the “2018 Annual Meeting”), in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is informing stockholders of such change. The exact time and location of the 2019 Annual Meeting will be specified in the Company’s proxy statement for the 2019 Annual Meeting.
Because the date of the 2019 Annual Meeting has been changed by more than 30 days from the anniversary of the 2018 Annual Meeting, a new deadline has been set for submission of proposals by stockholders intended to be included in the Company’s proxy statement for the 2019 Annual Meeting. In order for a proposal under Rule 14a-8 under the Exchange Act to be considered timely, it must be received by the Company on or prior to January 4, 2019 at the Company’s principal executive offices at 1000 Alfred Nobel Drive, Hercules, California 94547 and be directed to the attention of the Corporate Secretary. All such proposals must be in compliance with applicable laws and regulations in order to be considered for inclusion in the Company’s proxy statement for the 2019 Annual Meeting.
In addition, the Company’s Amended and Restated Bylaws require a stockholder to give advance notice of any proposal to conduct business, or to present a nomination of one or more candidates for election to the Board, that the stockholder wishes to bring before a meeting of the Company’s stockholders. Because the date of the 2019 Annual Meeting has been changed by more than 30 days from the anniversary of the 2018 Annual Meeting, written notice of any such stockholder proposal or nomination, which complies with the requirements set forth the Company’s Amended and Restated Bylaws, must be received by the Company’s Corporate Secretary at the Company’s principal executive offices at 1000 Alfred Nobel Drive, Hercules, California 94547 during the period beginning 120 days before the 2019 Annual Meeting and ending on the later of (i) 90 days before the 2019 Annual Meeting and (ii) 10 days after the earlier of the day on which notice of the date of the 2019 Annual Meeting was mailed and the day on which public disclosure of the date of the 2019 Annual Meeting was made (in other words, no earlier than December 24, 2018 and no later than January 23, 2019).
About BIO-RAD LABORATORIES, INC. (NYSE:BIO)
Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. Bio-Rad operates in two segments: Life Science and Clinical Diagnostics. The Company’s Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Company’s Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. Bio-Rad sells over 8,000 products and services to a client base consisting of scientific research, healthcare, education and government customers around the world.